Therefore, this study investigated whether the effect of CAY10683 (a selective HDAC2 inhibitor) combined with IM on CML cells resistant to IM was mainly achieved through inhibiting HDAC2. The gene discussed is HDAC2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.